To estimate the satisfactory response rate (SR%) with achieving maintenance, low-dose prednisone in acetylcholine receptor antibody–positive generalized myasthenia gravis.
In this retrospective study, we estimate the SR% as defined by (remission/minimal manifestations status for at least 6 months using 7.5 mg or less of prednisone daily, for maintenance treatment at 2, 4, and 6 years after symptoms onset) for patients who were not taking steroid-sparing immunosuppressant (SSI) as a primary outcome and for patients taking an SSI as a secondary outcome.
Forty-five patients were not taking an SSI at 2 years, 34 patients at 4 years, and 17 patients at 6 years; SR% was 44.4%, 64.7%, and 58.8%, respectively. Thirty-six patients were taking an SSI at 2 years, 22 patients at 4 years, and 15 patients at 6 years; the SR% was 50.0%, 45.4%, and 66.7%, respectively.
Nearly half of the generalized myasthenia gravis patients who were not taking an SSI achieved an SR.
*Neurology Division, Internal Medicine Department, King Abdulaziz University, Jeddah, Saudi Arabia; and
†Neurology Department, The University of Kansas Medical Center, Kansas City, KS.
Reprints: Mazen M. Dimachkie, MD, FAAN, Neuromuscular Section, Neurology Department, The University of Kansas Medical Center, 2100 West 36th Avenue, Mail Stop 2012, Kansas City, KS 66160 (e-mail: firstname.lastname@example.org).
The authors report no conflicts of interest.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.jcnmd.com).